Scarica l'app Stockscreener
19.41
0.36%
0.07
Dopo l'orario di chiusura:
19.41
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CSTL Giù?
Forum
Previsione
Precedente Chiudi:
$19.34
Aprire:
$19.51
Volume 24 ore:
2.39M
Relative Volume:
4.95
Capitalizzazione di mercato:
$563.05M
Reddito:
$219.79M
Utile/perdita netta:
$-57.47M
Rapporto P/E:
-9.0279
EPS:
-2.15
Flusso di cassa netto:
$-19.25M
1 W Prestazione:
-1.77%
1M Prestazione:
-1.27%
6M Prestazione:
-29.70%
1 anno Prestazione:
-29.90%
Intervallo 1D:
$19.24
$19.92
Intervallo di 1 settimana:
$18.81
$20.18
Portata 52W:
$14.59
$35.84
Castle Biosciences Inc Stock (CSTL) Company Profile
Nome
Castle Biosciences Inc
Settore
Industria
Telefono
866-788-9007
Indirizzo
505 S FRIENDSWOOD DRIVE, FRIENDSWOOD, TX
Confronta CSTL con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CSTL
Castle Biosciences Inc
|
19.41 | 555.80M | 219.79M | -57.47M | -19.25M | -2.15 |
|
TMO
Thermo Fisher Scientific Inc
|
484.79 | 174.60B | 43.21B | 6.58B | 6.17B | 17.29 |
|
DHR
Danaher Corp
|
209.14 | 143.04B | 24.01B | 3.41B | 4.86B | 4.70 |
|
IDXX
Idexx Laboratories Inc
|
664.16 | 52.17B | 4.04B | 985.66M | 774.34M | 12.01 |
|
A
Agilent Technologies Inc
|
120.29 | 32.42B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
190.23 | 30.62B | 15.50B | 1.33B | 2.16B | 7.34 |
Castle Biosciences Inc Stock (CSTL) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2023-12-14 | Iniziato | Guggenheim | Buy |
| 2023-01-05 | Iniziato | Scotiabank | Sector Outperform |
| 2022-01-07 | Iniziato | Stephens | Overweight |
| 2021-04-30 | Iniziato | Lake Street | Buy |
| 2020-11-10 | Iniziato | KeyBanc Capital Markets | Overweight |
| 2019-12-27 | Reiterato | Canaccord Genuity | Buy |
| 2019-08-19 | Iniziato | BTIG Research | Buy |
| 2019-08-19 | Iniziato | Canaccord Genuity | Buy |
| 2019-08-19 | Iniziato | Robert W. Baird | Outperform |
| 2019-08-19 | Iniziato | SVB Leerink | Outperform |
Mostra tutto
Castle Biosciences Inc Borsa (CSTL) Ultime notizie
Will Castle Biosciences Inc. outperform tech stocksMax Yield Daily Selections - mustnews.co.kr
Castle Biosciences Updates Bylaws for Improved Governance - TipRanks
CSTL SEC FilingsCastle Biosciences 10-K, 10-Q, 8-K Forms - Stock Titan
Price Clustering Detected in Castle Biosciences Inc. StockExit Ready Momentum Stock Watchlist Expanded - beatles.ru
Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV), Castle Biosciences (CSTL) and Regeneron (REGN) - The Globe and Mail
Castle Biosciences Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Castle Biosciences Reports Strong Q2 2025 Results - TipRanks
Barrett Business Reports Q2 GAAP EPS of $0.70, Beating Estimates by $0.01 - AInvest
Castle Biosciences, Inc. (NASDAQ:CSTL) Q2 2025 Earnings Call Transcript - Insider Monkey
Castle Biosciences Maintains Strong Buy Rating with $32 Price Target - AInvest
Castle Biosciences Raises Revenue Guidance Amid Growth and Challenges - AInvest
Robert W. Baird Sticks to Its Buy Rating for Castle Biosciences (CSTL) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: AbbVie, Castle Biosciences, and Regeneron - AInvest
Castle Biosciences’ Earnings Call: Growth Amid Challenges - TipRanks
Castle Biosciences, Inc. (CSTL) Q2 Earnings and Revenues Surpass Estimates - MSN
Castle Biosciences Reports Strong Q2 2025 Financial Results - MSN
Castle Biosciences Soars 22.52% on Strong Q2 Earnings - AInvest
Castle Biosciences Q2 2025 Earnings Call Highlights: Strong Revenue Growth Despite Challenges - AInvest
Castle Biosciences Inc (CSTL) Q2 2025 Earnings Call Highlights: Navigating Revenue Challenges ... - Yahoo Finance
Castle Biosciences Inc (CSTL) Q2 2025 Earnings Call Highlights: Navigating Revenue Challenges ... By GuruFocus - Investing.com Canada
Castle Biosciences Q2 2025 Earnings Exceed Expectations with $86.2M Revenue, $0.16 EPS, and Strong Gross Margin of 77% - AInvest
Castle Biosciences: A Strategic Bet on Personalized Oncology Diagnostics - AInvest
Transcript : Castle Biosciences, Inc., Q2 2025 Earnings Call, Aug 04, 2025 - MarketScreener
Castle Biosciences Outpaces Estimates And Ups Forecast - Finimize
Castle Biosciences Outpaces Expectations With Bright Forecast - Finimize
Earnings call transcript: Castle Biosciences Q2 2025 beats EPS forecast By Investing.com - Investing.com South Africa
Earnings call transcript: Castle Biosciences Q2 2025 beats EPS forecast - Investing.com
Medical testing provider Castle Bio raises annual revenue guidance - MarketScreener
Castle Biosciences Q2 2025 slides: Test volume surges 33% amid declining margins - Investing.com India
Castle Biosciences Reports Second Quarter 2025 Results - The Manila Times
Shareholders in Castle Biosciences (NASDAQ:CSTL) have lost 65%, as stock drops 10% this past week - simplywall.st
What drives Castle Biosciences Inc. stock priceMaximize gains with strategic stock entries - Jammu Links News
What is the dividend policy of Castle Biosciences Inc. stockHigh-octane gains - Jammu Links News
What are analysts’ price targets for Castle Biosciences Inc. in the next 12 monthsMaximize portfolio returns with smart trading - Jammu Links News
What catalysts could drive Castle Biosciences Inc. stock higher in 2025Invest smarter with expert trading signals - Jammu Links News
What are Castle Biosciences Inc. company’s key revenue driversOutstanding growth strategies - Jammu Links News
Should I hold or sell Castle Biosciences Inc. stock in 2025Phenomenal capital gains - Jammu Links News
What institutional investors are buying Castle Biosciences Inc. stockMaximize your portfolio’s earning potential - Jammu Links News
When is Castle Biosciences Inc. stock expected to show significant growthRapid portfolio appreciation - Jammu Links News
How volatile is Castle Biosciences Inc. stock compared to the marketGrow your wealth steadily and securely - Jammu Links News
How many analysts rate Castle Biosciences Inc. as a “Buy”Free Stock Selection - Jammu Links News
Castle Biosciences Q2 Earnings Preview: Analysts Expect $-0.50 EPS - AInvest
Castle Biosciences CSTL Q2 2025 Earnings Preview Upside Potential on Raised Revenue Forecast - AInvest
Some Confidence Is Lacking In Castle Biosciences, Inc. (NASDAQ:CSTL) As Shares Slide 26% - 富途牛牛
Published on: 2025-07-30 02:23:31 - metal.it
The True Test of Success - thebossmagazine.com
Castle Biosciences to Present at the Canaccord Genuity 45th Annual Growth Conference - GlobeNewswire
Healthcare Innovator Castle Biosciences Reveals Latest Growth Strategy at Major Investment Conference - Stock Titan
What Technical Tools Say About Castle Biosciences Inc. RecoveryConsistent Income Focused Trade List Analyzed - metal.it
Earnings Preview: Castle Biosciences, Inc. (CSTL) Q2 Earnings Expected to Decline - Yahoo Finance
Castle Biosciences, Revolution Medicines get FDA breakthrough statuses - MSN
Castle Biosciences Inc Azioni (CSTL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.96%
1.32%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):